Cases of myopia, or short-sightedness, are increasing rapidly around the world, and a new study suggests that our modern tendency to spend more time indoors could be a key driving factor. While we ...

Late in 2024, a comprehensive study published in the British Journal of Opthalmology claimed that “the global prevalence of ...

SEATTLE--(BUSINESS WIRE)--Kubota Vision Inc. (Kubota Vision), a clinical-stage specialty ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), ...

SEATTLE--(BUSINESS WIRE)--Kubota Vision Inc. (Kubota Vision), a clinical-stage specialty ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Prevalence of myopic macular degeneration increased 8.89 ...

Myopia, or the need for corrected vision to focus or see objects at a distance, has become a lot more common in recent decades. Some even consider myopia, also known as nearsightedness, an epidemic.

Prolonged near work in low luminance may accelerate myopia primarily by limiting retinal illumination through sustained accommodative miosis rather than by electronic screens per se.

The coronavirus pandemic is remaking the way children learn, and it could have an impact on their eyes. With schools shifting to online lessons at home, children are spending more time in front of ...

Cataract surgery in the highly myopic patient, typically defined by an axial length greater than 26 mm, represents one of the ...

If you've ever found yourself driving down the highway and noticed that billboards, traffic signs or vehicles in the distance appear blurry, chances are you're experiencing some form of myopia. This ...

The United States is fast becoming a nearsighted nation: More than 40% of Americans have myopia, and the number is climbing fast, especially for children. Experts aren’t sure why, but they believe ...

Basel, May 31, 2013 - Novartis has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for Lucentis ® (ranibizumab) to treat patients with visual impairment due ...